Recent Advances in Targeting ROS1 in Lung Cancer

ROS1 is a validated therapeutic target in NSCLC.In a phase I study, the multitargeted MET proto-oncogene, receptor tyrosine kinase/anaplastic lymphoma kinase/ROS1 inhibitor crizotinib demonstrated remarkable efficacy in ROS1rearranged NSCLCs and consequently gained approval by the United States Food and Drug Administration and by the European Medicines Agency in 2016.However, similar to other oncogene-driven lung cancers, ROS1-rearranged lung cancers treated with crizotinib eventually acquire resistance, leading to disease relapse.Novel ROS1 inhibitors and therapeutic strategies are therefore needed.Insights into the mechanisms of resistance to ROS1-directed tyrosine kinase inhibitors are now beginning to emerge and are helping to guide the development of new ROS1 inhibitors.This review discusses the biology and diagnosis of ROS1rearranged NSCLC, and current and emerging treatment options for this disease.Future challenges in the field are highlighted.